Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNYSE:PEN
CUSIPN/A
Phone510-748-3200
Debt
Debt-to-Equity RatioN/A
Current Ratio7.72
Quick Ratio5.84
Price-To-Earnings
Trailing P/E Ratio1,127.92
Forward P/E Ratio796.18
P/E Growth41.02
Sales & Book Value
Annual Sales$333.76 million
Price / Sales13.89
Cash Flow$0.1229 per share
Price / Cash1,101.30
Book Value$11.80 per share
Price / Book11.47
Profitability
EPS (Most Recent Fiscal Year)($0.01)
Net Income$4.65 million
Net Margins3.65%
Return on Equity1.13%
Return on Assets0.96%
Miscellaneous
Employees1,700
Outstanding Shares34,260,000
Market Cap$4,637.50
Penumbra (NYSE:PEN) Frequently Asked Questions
What is Penumbra's stock symbol?
Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
How were Penumbra's earnings last quarter?
Penumbra Inc (NYSE:PEN) issued its earnings results on Tuesday, May, 8th. The company reported $0.06 EPS for the quarter, beating the Zacks' consensus estimate of ($0.02) by $0.08. The business earned $102.70 million during the quarter, compared to analysts' expectations of $90.98 million. Penumbra had a net margin of 3.65% and a return on equity of 1.13%. The company's quarterly revenue was up 40.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.10) earnings per share. View Penumbra's Earnings History.
What price target have analysts set for PEN?
6 analysts have issued twelve-month price objectives for Penumbra's shares. Their predictions range from $140.00 to $180.00. On average, they anticipate Penumbra's stock price to reach $157.50 in the next year. This suggests a possible upside of 16.4% from the stock's current price. View Analyst Ratings for Penumbra.
What is the consensus analysts' recommendation for Penumbra?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Penumbra stock?
Here are some recent quotes from research analysts about Penumbra stock:
- 1. According to Zacks Investment Research, "Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California. " (6/26/2018)
- 2. Canaccord Genuity analysts commented, "We would stay buyers of PEN, which continues to be a top pick in S/Mid-cap med-tech. We picked up notable legislative progress out of Tennessee both noteworthy and positive for PEN as well as the AIS market in general." (4/5/2018)
Who are some of Penumbra's key competitors?
Some companies that are related to Penumbra include ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), ICU Medical (ICUI), Hill-Rom (HRC), Globus Medical (GMED), Insulet (PODD), Haemonetics (HAE), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Nevro (NVRO) and Mazor Robotics (MZOR).
Who are Penumbra's key executives?
Penumbra's management team includes the folowing people:
- Mr. Adam Elsesser, Co Founder, Chairman, Chief Exec. Officer and Pres (Age 56)
- Dr. Arani Bose M.D., Co-Founder, Chief Innovator and Director (Age 56)
- Mr. Sridhar N. Kosaraju, Chief Financial Officer and Head of Strategy (Age 40)
- Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 57)
- Mr. Daniel Donen Davis, Chief Commercial Officer & Pres of North America (Age 40)
Has Penumbra been receiving favorable news coverage?
Media stories about PEN stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Penumbra earned a coverage optimism score of 0.15 on Accern's scale. They also gave news headlines about the company an impact score of 47.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Penumbra's major shareholders?
Penumbra's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Xact Kapitalforvaltning AB (0.01%), State of Alaska Department of Revenue (0.01%) and Campbell & CO Investment Adviser LLC (0.01%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Institutional Ownership Trends for Penumbra.
Which major investors are buying Penumbra stock?
PEN stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Campbell & CO Investment Adviser LLC and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Penumbra.
How do I buy shares of Penumbra?
Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Penumbra's stock price today?
One share of PEN stock can currently be purchased for approximately $135.35.
How big of a company is Penumbra?
Penumbra has a market capitalization of $4.64 billion and generates $333.76 million in revenue each year. The company earns $4.65 million in net income (profit) each year or ($0.01) on an earnings per share basis. Penumbra employs 1,700 workers across the globe.
How can I contact Penumbra?
Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]
MarketBeat Community Rating for Penumbra (NYSE PEN)
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
